{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT03742414",
      "orgStudyIdInfo": {
        "id": "48199"
      },
      "secondaryIdInfos": [
        {
          "id": "1U01AI147462-01A1",
          "type": "NIH",
          "link": "https://reporter.nih.gov/quickSearch/1U01AI147462-01A1"
        }
      ],
      "organization": {
        "fullName": "Harvard School of Public Health (HSPH)",
        "class": "OTHER"
      },
      "briefTitle": "Seal, Stopping Eczema and Allergy Study",
      "officialTitle": "SEAL (Stopping Eczema and ALlergy) Study: Prevent the Allergic March by Enhancing the Skin Barrier"
    },
    "statusModule": {
      "statusVerifiedDate": "2024-10",
      "overallStatus": "ACTIVE_NOT_RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2021-06-30",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2028-05-31",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2028-06-30",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2018-10-30",
      "studyFirstSubmitQcDate": "2018-11-13",
      "studyFirstPostDateStruct": {
        "date": "2018-11-15",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-06-25",
      "lastUpdatePostDateStruct": {
        "date": "2025-06-29",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR_INVESTIGATOR",
        "investigatorFullName": "Kari Nadeau, MD, PhD",
        "investigatorTitle": "Chair, Department of Environmental Health",
        "investigatorAffiliation": "Harvard School of Public Health (HSPH)"
      },
      "leadSponsor": {
        "name": "Kari Nadeau, MD, PhD",
        "class": "OTHER"
      },
      "collaborators": [
        {
          "name": "National Jewish Health",
          "class": "OTHER"
        },
        {
          "name": "University of Chicago",
          "class": "OTHER"
        },
        {
          "name": "Children's Hospital Medical Center, Cincinnati",
          "class": "OTHER"
        },
        {
          "name": "Harvard School of Public Health (HSPH)",
          "class": "OTHER"
        },
        {
          "name": "Stanford University",
          "class": "OTHER"
        },
        {
          "name": "National Institute of Allergy and Infectious Diseases (NIAID)",
          "class": "NIH"
        },
        {
          "name": "King's College London",
          "class": "OTHER"
        },
        {
          "name": "Guy's and St Thomas' NHS Foundation Trust",
          "class": "OTHER"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).",
      "detailedDescription": "This is a randomized, controlled, parallel design, open-label phase 2 clinical study to compare the efficacy of a proactive treatment arm versus the reactive arm, for the prevention of atopic dermatitis in children at high risk of food allergy. We will recruit 398 infants who have signs of dry skin or atopic dermatitis between 0-12 weeks of life.\n\nThe aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA)."
    },
    "conditionsModule": {
      "conditions": [
        "Eczema, Infantile",
        "Eczema",
        "Atopic Dermatitis Eczema",
        "Atopic Dermatitis"
      ],
      "keywords": [
        "Dermatitis",
        "Dry skin",
        "Food allergy",
        "Moisturizer"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "interventionModelDescription": "This is a randomized, controlled, parallel design trial designed for children (total n = 398) who have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a tri-lipid skin barrier cream (Epiceram) or moisturizer and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).",
        "primaryPurpose": "PREVENTION",
        "maskingInfo": {
          "masking": "DOUBLE",
          "whoMasked": [
            "PARTICIPANT",
            "INVESTIGATOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 398,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Control arm (Standard of care)",
          "type": "ACTIVE_COMPARATOR",
          "description": "The study doctors will provide standard of care with routine reactive topical products for atopic dermatitis flares",
          "interventionNames": [
            "Other: Standard of Care"
          ]
        },
        {
          "label": "Active Intervention arm (proactive treatment)- Epiceram",
          "type": "EXPERIMENTAL",
          "description": "Participants will receive proactive sequential skin care with the twice-daily use of a tri-lipid skin barrier cream (SBC). Clinically apparent eczema in this group will be managed with a short course of topical steroids (fluticasone propionate cream and/or hydrocortisone).",
          "interventionNames": [
            "Combination Product: Tri-lipid skin barrier cream (Epiceram)",
            "Combination Product: Fluticasone propionate Cream 0.05%"
          ]
        }
      ],
      "interventions": [
        {
          "type": "COMBINATION_PRODUCT",
          "name": "Tri-lipid skin barrier cream (Epiceram)",
          "description": "The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).",
          "armGroupLabels": [
            "Active Intervention arm (proactive treatment)- Epiceram"
          ]
        },
        {
          "type": "COMBINATION_PRODUCT",
          "name": "Fluticasone propionate Cream 0.05%",
          "description": "Proactive use of fluticasone proprionate cream for inflammation of the skin, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).",
          "armGroupLabels": [
            "Active Intervention arm (proactive treatment)- Epiceram"
          ]
        },
        {
          "type": "OTHER",
          "name": "Standard of Care",
          "description": "Participants' eczema will be managed by their primary physician, i.e. standard of care with routine reactive topical products for atopic dermatitis flares.",
          "armGroupLabels": [
            "Control arm (Standard of care)"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "number of foods each participant is sensitized to",
          "description": "Sensitization is defined as food-specific IgE \\> 0.1 kU/L",
          "timeFrame": "2 years"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "The per-subject cumulative number of proven Food Allergy",
          "description": "Double-blind placebo-controlled oral food challenges used",
          "timeFrame": "2 years"
        },
        {
          "measure": "Number of foods each participant is sensitized to",
          "description": "Sensitization is defined as food-specific skin prick test (SPT) ≥ 1 mm",
          "timeFrame": "24 months of age"
        },
        {
          "measure": "Number of foods each participant is sensitized to",
          "description": "Sensitization is defined as food-specific skin prick test (SPT) ≥ 3 mm.",
          "timeFrame": "24 months of age"
        },
        {
          "measure": "Presence, duration, and severity of dry skin and/or AD by clinical assessment",
          "description": "Patient-oriented SCORAD (PO-SCORAD) application used",
          "timeFrame": "Baseline, 12, and 24 months of age and as necessary"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Participants who develop early onset visible dry skin or atopic dermatitis up to and equal to 12 weeks of age.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. In good general health as evidenced by medical history\n4. No known adverse reaction to any of the study medications, their components or excipients\n\nExclusion Criteria:\n\n1. Infants \\<3kg body weight\n2. Infants with a chronic disease requiring therapy (e.g. heart disease, diabetes, serious neurological defects, immunodeficiency)\n3. Known moderate to severe cutaneous skin disorder other than AD, including but not limited to cutaneous mastocytosis, bullous skin disease, pustular skin disease, neonatal HSV, aplasia, and albinism\n4. Parents or guardians unwilling to sign consent\n5. Current participant or participation since birth in any interventional study\n6. Investigator or designee considers that the participant or parent/guardian would be unsuitable for inclusion in the study (for ex/ long stay in NICU)\n7. A course of antibiotics in infant within 7 days of enrollment\n8. Any known food allergies",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "1 Week",
      "maximumAge": "12 Weeks",
      "stdAges": [
        "CHILD"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Kari Nadeau, MD, PhD",
          "affiliation": "Harvard",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Sean N. Parker Center for Allergy & Asthma Research at Stanford University",
          "city": "Palo Alto",
          "state": "California",
          "zip": "94304",
          "country": "United States",
          "geoPoint": {
            "lat": 37.44188,
            "lon": -122.14302
          }
        },
        {
          "facility": "Division of Pediatric Allergy and Clinical Immunology, National Jewish Health",
          "city": "Denver",
          "state": "Colorado",
          "zip": "80206",
          "country": "United States",
          "geoPoint": {
            "lat": 39.73915,
            "lon": -104.9847
          }
        },
        {
          "facility": "University of Chicago",
          "city": "Chicago",
          "state": "Illinois",
          "zip": "60637",
          "country": "United States",
          "geoPoint": {
            "lat": 41.85003,
            "lon": -87.65005
          }
        },
        {
          "facility": "Cincinnati Children's Hospital Medical Center",
          "city": "Cincinnati",
          "state": "Ohio",
          "zip": "45229",
          "country": "United States",
          "geoPoint": {
            "lat": 39.12711,
            "lon": -84.51439
          }
        },
        {
          "facility": "• King's College London and Guy's and St. Thomas' NHS Foundation Trust, UK",
          "city": "London",
          "state": "London",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 51.50853,
            "lon": -0.12574
          }
        }
      ]
    },
    "referencesModule": {
      "seeAlsoLinks": [
        {
          "label": "The Sean N. Parker Center for Allergy and Asthma Research at Stanford University",
          "url": "http://med.stanford.edu/allergyandasthma/about-us.html"
        },
        {
          "label": "SEAL study information",
          "url": "https://sealstudy.sites.stanford.edu/"
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO",
      "description": "No current plan to share data"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D003876",
          "term": "Dermatitis, Atopic"
        },
        {
          "id": "D004485",
          "term": "Eczema"
        },
        {
          "id": "D003872",
          "term": "Dermatitis"
        },
        {
          "id": "D005512",
          "term": "Food Hypersensitivity"
        }
      ],
      "ancestors": [
        {
          "id": "D012873",
          "term": "Skin Diseases, Genetic"
        },
        {
          "id": "D030342",
          "term": "Genetic Diseases, Inborn"
        },
        {
          "id": "D009358",
          "term": "Congenital, Hereditary, and Neonatal Diseases and Abnormalities"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D017443",
          "term": "Skin Diseases, Eczematous"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C539259",
          "term": "EpiCeram"
        },
        {
          "id": "D059039",
          "term": "Standard of Care"
        }
      ],
      "ancestors": [
        {
          "id": "D019984",
          "term": "Quality Indicators, Health Care"
        },
        {
          "id": "D011787",
          "term": "Quality of Health Care"
        },
        {
          "id": "D006298",
          "term": "Health Services Administration"
        },
        {
          "id": "D017530",
          "term": "Health Care Quality, Access, and Evaluation"
        }
      ]
    }
  },
  "hasResults": false
}